Sphenopalatine (pterygopalatine) ganglion stimulation and cluster headache: New hope for ye who enter here

Peter J Goadsby

Cluster headache is a devastating primary headache disorder (1) that in its chronic form presents as if approached and consumed by three beasts. Medically intractable chronic cluster headache (2) is among the most challenging of ailments headache specialists can be called on to treat. While we have seen important advances in understanding the disorder with brain imaging (3,4), and the conduct of randomized controlled trials in the last decade (5,6), many patients still suffer far too much. Research in the field is at best pathetically funded; as an example the writer is unaware of any dedicated projects involving the United States National Institutes of Health or United Kingdom (UK) Medical Research Council. Yet at some 0.1% of the population (7,8), cluster headache is as common as multiple sclerosis in the UK (9). Developments are welcome, and this issue of the Journal offers a new twist based on our understanding of the pathophysiology of the condition (10)—the involvement of the cranial parasympathetic outflow through the sphenopalatine ganglion (11).

Cluster headache is one of the trigeminal autonomic cephalalgias (TACs) (12). These syndromes have the signature features of lateralization of the phenotype: pain, cranial autonomic features (13), features typically associated with migraine, such as photophobia (14), and very distinct responses to treatment, such as the response in paroxysmal hemicrania (15) and hemicrania continua (16) to indomethacin (17,18). When clinicians consider the phenotype, and as the collection group term TAC implies, cranial autonomic features, viz. conjunctival injection, lacrimation, nasal congestion or rhinorrhea, eyelid edema, forehead or facial sweating or flushing, a sense of aural fullness or miosis or ptosis, come readily to mind. One or more is usually found in any patient and, importantly, we have a very good grasp of the anatomy and physiology of these symptoms.

To begin with a note of clarification, one of the key structures in the expression of cranial autonomic symptoms is the sphenopalatine (SPG) (19), sometimes called pterygopalatine (20), ganglion. The latter term seems to have invaded the literature as the SPG sits in the pterygopalatine fossa. Given that Gray’s description was very complete, while either term seems usable, one could argue historical precedence for SPG. The outflow pathway for the cranial autonomic pathway begins in the superior salivatory nucleus in the pons, which can be excited by trigeminal afferents (21) and is certainly connected to a trigeminal input (22). The outflow proceeds through the seventh cranial (facial) nerve without synapsing in the geniculate ganglion. The important synapses are in the SPG, and to a lesser extent in the otic and carotid miniganglia (23–25).

The SPG synapse is a hexamethonium-sensitive classic nicotinic ganglion, and there is nitric oxide synthase located within the SPG (26). When activated SPG stimulation increases cerebral blood flow (27,28) in the absence of a change in brain glucose utilization (29): neurogenic cerebral vasodilation. SPG activation plays a pivotal role in brainstem-induced changes in cerebral blood flow, such as those seen from locus coeruleus (25), and when activated releases vasoactive intestinal polypeptide (VIP) at the cortex (30) and can have its effects reversed if VIP is blocked (31). The SPG also possesses immunoreactivity (32) for pituitary adenylate cyclase-activating peptide (PACAP) (33,34), so that each of the PAC1 and VPAC1 and VPAC2 receptors (35) could be involved in its activation (36).

On this basis the SPG has been proposed as a target for the treatment of cluster headache. Schoenen and...
colleagues (11) here present a fascinating sham-controlled randomized study of SPG stimulation to treat cluster headache. Certainly targeting the SPG is not new (37), and blockade with local anesthetic (38) or radiofrequency (39) approaches are well reported. The authors here have used a novel, miniaturized stimulator with an external control device targeted directly to the SPG by implantation. They report on 28 patients with chronic cluster headache who had a 67% pain relief outcome at 15 minutes. Perhaps more remarkable, 10 patients had a reduced frequency of attack during the treatment period, suggesting it may be better thought of as a cluster headache preventive device. The device seems well tolerated and safe, with some apparent learning curve to successful implantation. The most interesting side effect is what is described as localized loss of sensation in distribution of the maxillary nerve; this is predictable from the anatomical arrangement wherein the SPG drapes over and near the maxillary nerve in the pterygopalatine ganglion.

What I find exciting about this approach is the rational development of a new therapy based solidly on knowledge of the anatomy and physiology of the condition—translational medicine at work in a way the headache community can be proud of. With every new development in cluster headache my practice day brightens; even if it is not usable immediately, since it offers hope for tomorrow. Patients are looking to us—the headache community—for new understanding and new treatments of their problems. It is our collective role, nay responsibility, to see that patients with chronic cluster headache do not have to... abandon all hope.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest
I have consulted for the sponsor Autonomic Technology Industries, a fact declared to the Journal before accepting the commission for this editorial.

References
1. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders: 2nd ed. Cephalalgia 2004; 24(Suppl 1): 1–160.
2. Goadsby PJ, Schoenen J, Ferrari MD, et al. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia 2006; 26: 1168–1170.
3. May A. Cluster headache: Pathogenesis, diagnosis, and management. Lancet 2005; 366: 843–855.
4. Sprenger T and Goadsby PJ. What has functional neuroimaging done for primary headache... and for the clinical neurologist? J Clin Neurosci 2010; 17: 547–553.
5. May A, Leone M, Afra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006; 13: 1066–1077.
6. Goadsby PJ. Trigeminal autonomic cephalalgias. Continuum (Minneap Minn) 2012; 18: 883–895.
7. Sjaastad O and Bakkeeteg LS. Cluster headache prevalence Vaga study of headache epidemiology. Cephalalgia 2003; 23: 528–533.
8. Evers S, Fischera M, May A, et al. Prevalence of cluster headache in Germany: Results of the epidemiological DMKG study. J Neurol Neurosurg Psychiatry 2007; 78: 1289–1290.
9. Ford HL, Gerry E, Johnson M, et al. A prospective study of the incidence, prevalence and mortality of multiple sclerosis in Leeds. J Neurol 2002; 249: 260–265.
10. Goadsby PJ. Pathophysiology of cluster headache: A trigeminal autonomic cephalalgia. Lancet Neurol 2002; 1: 37–43.
11. Schoenen J, Jensen RH, Lanteri-Minet M, et al. Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-I: A randomized, sham-controlled study. Cephalalgia. Epub ahead of print 14 February 2013. DOI: 10.1177/0333005012473667.
12. Goadsby PJ and Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic features, including new cases. Brain 1997; 120: 193–209.
13. Lai T-H, Fuh J-L and Wang S-J. Cranial autonomic symptoms in migraine: Characteristics and comparison with cluster headache. J Neurol Neurosurg Psychiatry 2009; 80: 1116–1119.
14. Irimia P, Cittadini E, Paemeleire K, et al. Unilateral photophobia or phonophobia in migraine compared with trigeminal autonomic cephalalgias. Cephalalgia 2008; 28: 626–630.
15. Cittadini E, Matharu MS and Goadsby PJ. Paroxysmal hemicrania: A prospective clinical study of 31 cases. Brain 2008; 131: 1142–1155.
16. Cittadini E and Goadsby PJ. Hemicrania continua: A clinical study of 39 patients with diagnostic implications. Brain 2010; 133: 1973–1986.
17. Sjaastad O and Dale I. A new (?) clinical headache entity “chronic paroxysmal hemicrania” 2. Acta Neurol Scand 1976; 54: 140–159.
18. Sjaastad O and Spierings EL. “Hemicrania continua”: Another headache absolutely responsive to indomethacin. Cephalalgia 1984; 4: 65–70.
19. Gray H. Anatomy of the human body (www.bartleby.com/107/) Philadelphia: Lea & Febiger. 1918.
20. Warwick R and Williams P. Gray’s anatomy, 35th edn. Edinburgh: Longman Group Ltd, 1973.
21. Knight YE, Classen J, Lasalandra MP, et al. Patterns of fos expression in the rostral medulla and caudal pons evoked by noxious craniovascular stimulation and periaqueductal gray stimulation in the cat. Brain Res 2005; 1045: 1–11.
22. Spencer SE, Sawyer WB, Wada H, et al. CNS projections to the pterygopalatine parasympathetic preganglionic neurons in the rat: A retrograde transneuronal viral cell body labeling study. *Brain Res* 1990; 534: 149–169.

23. Suzuki N, Hardebo JE and Owman C. Origins and pathways of cerebrovascular vasoactive intestinal polypeptide-positive nerves in rat. *J Cereb Blood Flow Metab* 1988; 8: 697–712.

24. Gibbins IL, Brayden JE and Bevan JA. Perivascular nerves with immunoreactivity to vasoactive intestinal polypeptide in cephalic arteries of the cat: Distribution, possible origins and functional implications. *Neuroscience* 1984; 13: 1327–1346.

25. Goadsby PJ, Lambert GA and Lance JW. The peripheral pathway for extracranial vasodilatation in the cat. *J Auton Nerv Syst* 1984; 10: 145–155.

26. Goadsby PJ, Uddman R and Edvinsson L. Cerebral vasodilatation in the cat involves nitric oxide from parasympathetic nerves. *Brain Res* 1996; 707: 110–118.

27. Goadsby PJ. Characteristics of facial nerve elicited cerebral vasodilatation determined with laser Doppler flowmetry. *Am J Physiol* 1991; 260: R255–R262.

28. Seylaz J, Hara H, Pinard E, et al. Effect of stimulation of the sphenopalatine ganglion on cortical blood flow in the rat. *J Cereb Blood Flow Metab* 1988; 8: 875–878.

29. Goadsby PJ. Effect of stimulation of the facial nerve on regional cerebral blood flow and glucose utilization in cats. *Am J Physiol* 1989; 257: R517–R521.

30. Goadsby PJ and Shelley S. High frequency stimulation of the facial nerve results in local cortical release of vasoactive intestinal polypeptide in the anesthetised cat. *Neurosci Lett* 1990; 112: 282–289.

31. Goadsby PJ and Macdonald GJ. Extracranial vasodilatation mediated by VIP (vasoactive intestinal polypeptide). *Brain Res* 1985; 329: 285–288.

32. Martin F, Baeres M and Moller M. Origin of PACAP-immunoreactive nerve fibers innervating the subarachnoidal blood vessels of the rat brain. *J Cereb Blood Flow Metab* 2004; 24: 628–635.

33. Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): Discovery and current status of research. *Regul Pept* 1992; 37: 287–303.

34. Boni LJ, Ploug KB, Olesen J, et al. The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. *Cephalalgia* 2009; 29: 837–847.

35. Akerman S and Goadsby PJ. VPAC1 and PAC1 receptor antagonists inhibit activation of the parasympathetic outflow to the cranial vasculature to prevent autonomic responses and neuronal firing in the trigeminocervical complex. *Cephalalgia* 2009; 29(Suppl 1): 130.

36. Henrik S, Steffen B, Wienecke T, et al. PACAP38 induces migraine-like attacks and vasodilatation—a causative role in migraine pathogenesis? *Brain* 2009; 132: 16–25.

37. Meyer JS, Binns PM, Ericsson AD, et al. Sphenopalatine ganglionectomy for cluster headache. *Arch Otolaryngol* 1970; 92: 475–484.

38. Kitrelle JP, Grouse DS and Seybold ME. Cluster headache: Local anesthetic abortive agents. *Arch Neurol* 1985; 42: 496–498.

39. Narouze S, Kapural L, Casanova J, et al. Sphenopalatine ganglion radiofrequency ablation for the management of chronic cluster headache. *Headache* 2009; 49: 571–577.